Biotechnology
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug inChina. - XPOVIO® as a monotherapy in patients with relap...
2025-07-28 18:49
2453
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for canc...
2025-07-28 10:40
1876
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials inSingapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therap...
2025-07-28 07:33
1758
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has design...
2025-07-25 22:59
3777
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and...
2025-07-25 10:30
2953
Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887". The clinical-stage biotech company priced its I...
2025-07-25 09:00
3082
Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378
CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB37...
2025-07-23 21:31
2606
Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will take place inShanghai, China, from September 9–12, 2025, co-hosted by Chinese Stomatological Association and Reed Sinopharm Exhibitions. Organized an...
2025-07-23 17:53
2163
Singapore-Based Innovative Biomedical Start-Up Achieves 'Strategic Triumph' to Conquer Chinese Med-Tech Market
* NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people * Syntellix' product approval for China is the largest and most important success in the company's history; product approval inChina was the company's most important strat...
2025-07-23 15:35
2920
BostonGene Receives Frost & Sullivan's 2025 North American Enabling Technology Leadership Award for Redefining Precision Oncology with AI and Multiomics Innovation
BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 /PRNewswire/ -- Frost & Sullivan has named BostonGene the recipient of the 2025...
2025-07-22 22:00
2076
Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific
SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving inAsia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp o...
2025-07-22 10:07
2784
CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area
SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in
June with a record-breaking 109,056 attendees, underscoring strong demand within
China's thriving pharma industry.
Building on this success, CPHI & PMEC Shenzhen 2025
2025-07-21 14:31
2120
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network,ziresovir (10mg) has been included in ...
2025-07-16 09:00
2265
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
* FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistan...
2025-07-16 08:54
1830
AXA and China Biotech Services Sign Memorandum of Understanding
Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 /PRNewswire/ -- AXA China Region Insurance Company (Bermuda) Limited, together with AXA International Reinsurance (Shanghai) Company Limited ("AXA"), is pleased to announce th...
2025-07-15 15:23
2013
Divamics' AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners
SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of B...
2025-07-15 07:31
1618
LABCONNECT APPOINTS MITCHELL BLUMENFELD AS CHIEF FINANCIAL OFFICER
JOHNSON CITY, Tenn., July 15, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Mitch Blumenfeld as its Chief Financial Officer, effective August 4, 2025. Mitch joins LabConnect with proven experience as Chief Financial Officer for high-growth companies in multiple industr...
2025-07-15 02:56
1688
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 /PRNewswire/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generati...
2025-07-14 15:00
1503
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
* Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) * 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse l...
2025-07-14 12:43
1389
Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery,...
2025-07-11 23:08
3618
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 310 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Hyundai Motor Group Fosters Collaboration with Hydrogen Industry Leaders at Hydrogen Council Global CEO Summit
[Picked up by 295 media titles]
2025-12-04 15:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
3550
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3061
